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Abstract 
Doxycycline is an antibiotic used in the treatment of a variety of inflammatory 
conditions, including periodontitis. Apart from its antimicrobial properties, this drug 
also has independent anti-inflammatory effects at sub-antimicrobial doses. The 
present study aimed to investigate the effects of low-doses of doxycycline (LDD) on 
cytokine production by human monocytic cells challenged with the periodontal 
pathogen Aggregatibacter actinomycetemcomitans, for up-to 6 hours. The 
simultaneous regulation of twelve cytokines were measured by a Human Cytokine 
Array Kit. To validate the array findings, selected cytokines were also measured by 
enzyme-linked immunosorbant assay (ELISA). A. actinomycetemcomitans stimulated 
the production of tumor necrosis factor (TNF)-α, interleukin (IL)-1α, IL-1β, IL-6 and 
IL-8 by the cells after 6 hours of challenge, and doxycycline significantly inhibited 
this effect. The kinetics of this regulation demonstrated an early (within 2 hours) and 
significant (P<0.05) inhibition of pro-inflammatory cytokines, with a mild (0.5-fold) 
up-regulation of the anti-inflammatory cytokine IL-10. The results indicate that LDD 
acts as an anti-inflammatory agent in human monocytic cells stimulated with A. 
actinomycetemcomitans. This model provides clear evidence that some of the 
clinically proven benefits of LDD may be related to its ability to regulate 
inflammatory mediator release by monocytic cells. This property may contribute to 
the clinically proven benefits of this antibiotic as an adjunctive treatment for 
periodontitis. 
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1. Introduction 
Periodontitis is an inflammatory condition caused by the accumulation of bacteria on 
tooth surfaces in the form of oral biofilms (1, 2). More than 700 bacterial species 
colonize the subgingival area but studies suggest that the presence of relatively few 
key species may be causally related to periodontitis. Aggregatibacter 
actinomycetemcomitans (A. actinomycetemcomitans) is an important pathogen in 
severe and recurrent forms of this disease (3, 4). A. actinomycetemcomitans has been 
implicated as a key etiological agent in localized aggressive periodontitis, where this 
species can be detected in nearly 90 % of the patients, and in severe chronic 
periodontitis, where it may be present in between 30% - 50 % of patients (5-7). This 
bacterial species possesses many virulence factors that are thought to be involved in 
the processes of alveolar bone loss and connective tissue destruction (8-11).Although, 
A. actinomycetemcomitans is primarily considered as an oral pathogen, on occasions 
the organism can be detected in the systemic circulation (12, 13). The levels of A. 
actinomycetemcomitans have been shown to correlate with an excessive host 
inflammatory response in susceptible individuals as characterized by enhanced 
concentrations of pro-inflammatory or reduced levels of anti-inflammatory cytokines 
such as interleukin (IL)-10 (14-18). 
The production of cytokines in response to periodontal bacteria includes contributions 
from a variety of cell types, but it is clear that monocytes are one of the most 
important sources within the gingival tissues (3, 19, 20). Monocytes secrete a wide 
variety of cytokines including IL-1 β, tumor necrosis factor (TNF)-α and IL-18 in 
response to periodontal pathogens which in turn play a major role in the initiation of 
protective immune responses in the periodontium (21-24). However, extensive release 
of pro-inflammatory cytokines such as TNF-α may harm the host by accelerating 
inflammation and activating bone and tissue destruction (25, 26). It is very likely that 
imbalances in cytokine production determine the extent of periodontal tissue 
destruction in susceptible individuals. Therefore modulating immunoinflammatory 
response to the bacterial exposure is an important concept in the treatment of various 
inflammatory diseases including periodontal disease (27, 28). 
Doxycycline, a member of the tetracycline family of antibiotics, has been approved by 
the United States Food and Drug Administration (FDA) as a host modulatory agent 
for use as an adjunct to conventional therapy for the treatment of chronic periodontitis 
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(7, 29, 30). Approval of doxycycline, more specifically subantimicrobial dose 
doxycycline was based on its ability to inhibit the activity of matrix 
metalloproteinases (MMPs). The MMPs are thought to be responsible for degradation 
of periodontal connective tissue (31). It is also known that MMPs are induced in 
response to a range of cytokines, including IL-1α and TNF-α (32, 33).  
However, it is unclear to what extent this low-doses of doxycycline is acting directly 
on MMP activity or if this reduced activity reflects a generalised anti-inflammatory 
effect (34-37). Improving our knowledge of host cytokine regulation in response to 
bacterial challenge is fundamental to understanding the clinical course of the disease 
and developing novel treatment strategies for periodontitis (38, 39). The clinical 
impact of LDD in modulating MMP activity is well-described, but its impact on the 
production of cytokines by monocytes is incomplete. Hence, this study aimed to 
investigate the effect of LDD on the regulation of a broad spectrum of inflammatory 
mediators by monocytic cells challenged with A. actinomytetemcomitants, as an in 
vitro model for periodontal infection. 
 
2. Materials and Methods 
2.1 Bacterial stimuli and materials 
Supernatants were obtained from cultures of A. actinomycetemcomitans Y4. Cultures 
were grown in Tryptic Soy Broth (Difco) with 0.6% yeast extract in an anaerobic 
chamber containing an atmosphere of 80% v/v N2, 10% v/v H2, and 10% v/v CO2. 
Cultures were grown to approximately 5x107 colony forming units/ml and harvested 
by centrifugation at 10,000g for 15 min at 4°C. The culture supernatants were 
collected, filter-sterilized (0.2µm) and stored at -80°C until used. The supernatant was 
directly diluted in culture medium to a final dilution of 1:250, a concentration which 
has been shown to induce cytokine production in the absence of cell toxicity (22). 
Commercially obtained lipopolysaccharide (LPS) from Escherichia coli 026:B6 
(Sigma-Aldrich, UK) was used as a positive control. Doxycycline hyclate (Sigma- 
Aldrich, UK) was dissolved in distilled water (stock of 50 mg/ml) and filter-sterilized 
(0.2µm). 
 
2.2 Cell lines, cell culture, and reagents 
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The myelomonocytic cell line, MonoMac-6 (40) was obtained from the German 
Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). 
MonoMac-6 cells were cultured in RPMI-Glutamax (Gibco BRL Life Technologies, 
UK) supplemented with 10% fetal bovine serum (Bio-Whittaker, Maryland), 1% 
nonessential amino acids (Gibco BRL), 1% sodium pyruvate (Gibco BRL) and 9 
µg/ml bovine insulin (Sigma-Aldrich, UK). The assays were performed with cells at a 
density of 1x106 cells per ml. 
 
2.3 Isolation of monocytes from PBMCs 
Peripheral blood was obtained from healthy adult volunteers by venous puncture 
following approval of the protocol by the East London and City Health Authority 
London Research Ethnics Committee. Human peripheral blood mononuclear cells 
(PBMCs) were separated by density gradient centrifugation using Ficoll-Paque Plus 
(Amersham Biosciences) according to the manufacturer’s instructions. Purified 
monocytes were isolated from the PBMCs as described previously (22). Briefly, the 
cell layer containing mononuclear cells was collected and washed twice with PBS 
containing EDTA (2mM) and bovine serum albumin (2%). Purified monocytes were 
isolated using negative selection that involves depletion of T cells and B cells using 
the Monocyte Isolation Kit II (Miltenyibiotec, Bergisch Gladbach, Germany). The 
purity of isolated monocytes was evaluated by flow cytometry on a FACScan flow 
cytometer (Becton Dickonson) using a CD14 FITC-conjugated antibody. Purified 
monocytes were re-suspended in RPMI-Glutamax (Gibco BRL Life Technologies, 
UK) supplemented with 10% fetal bovine serum (Bio-Whittaker, Maryland). The 
assays were performed with cells at a density of 1x106 cells per ml. 
 
2.4 Cell viability assays 
Cell viability was determined by measurement of lactate dehydrogenase (LDH) 
release using the CytoTox 96 non-radioactive cytotoxicity assay (Promega, UK). In 
brief, MonoMac-6 cells or primary human monocytes were exposed to LDD (5-25 
µg/ml) or bacterial supernatants then incubated for 6 hours at 37°C. 50 µl/well 
supernatant was carefully removed and transferred into an optically clear 96-well 
plate. Reaction solution was added followed by incubation for 30 min in darkness. 
The enzyme reaction was then stopped by the addition of 1N HCl and the absorbance 
was measured using a spectophotometric plate reader at 490nm (Model 680, Bio-Rad 
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Laboratories). The activity of the enzyme released from damaged cells into the 
supernatant was measured, and was expressed as a percentage of the total LDH 
activity released from cells lysed by exposure to 0.1% Triton X-100 for 45 min. 
 
2.5 Measurement of cytokine production 
The cells were seeded in 96-well plates at density of 1x106 cells/ml and incubated in 
the presence of bacterial supernatant from A. actinomycetemcomitans strain Y4 with 
or without doxycycline at indicated concentrations (5-25 µg/ml) up to 6 hours at 37°C 
in a 5% CO2 atmosphere. To assay cytokine production, the cell free culture 
supernatants were collected by centrifuging at 1000 rpm for 5 minutes and stored at -
80°C until the cytokine assays were performed. The concentrations of TNF-α, IL-1α, 
IL-1β and IL-6, IL-8 were determined by an enzyme-linked immunosorbant assay 
(ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer's protocols. The absorbance at 450 nm was read using a microplate 
reader (Model 680, Bio-Rad Laboratories) with a wavelength correction set at 570nm. 
A standard curve was generated using a four parameter logistic (4-PL) curve-fit 
(Microsoft Office Excel) for each set of samples assayed. The values of the samples 
were assigned according to the standard curve. The simultaneous regulation of 12 
cytokines was assessed in the culture supernatants using multiplex immunoassays. 
The Proteoplex 16 well Human Cytokine Array Kit, (Merck Biosciences, UK) was 
used for the assessment of TNF-α, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, 
IL-12, IFN-γ and GM-CSF. The minimum detectable concentration in this assay was 
5 pg/ml for each cytokine. The use of both ELISA and Proteoplex methods in the 
investigation of these inflammatory mediators provides a better validation and ensures 
the methodological repeatability of the results.  
 
2.6 Statistical analysis 
The significance of differences between the control (A. actinomycetemcomitans) and 
test groups (A. actinomycetemcomitans ± LDD) were assessed by one-way ANOVA 
and Bonferoni Post tests, using the GraphPad Prism Version 4.00 software. P<0.05 
values were considered statistically significant. The data are expressed as mean ± 
standard deviation (SD) in each group. 
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3. Results 
Firstly, the potential cytotoxic effects of LDD (up to 25µg/ml) were investigated. 
There was no significant increase in LDH release, as a marker of cell damage, in cells 
co-cultured with LDD, compared to the control (Table 1). Hence, these concentrations 
were deemed suitable for further experiments. Exposure of MonoMac-6 cells to 
culture supernatants of A. actinomycetemcomitans for 6 h significantly induced the 
production of IL-1α, IL-1β, IL-6, IL-8 and TNF-α by the cells (Table 2). To determine 
the effects of LDD on the production of these pro-inflammatory cytokines, two 
different doses of the drug (10 µg/ml and 25 µg/ml) were added to the cells at the 
same time as the challenge with the culture supernatants. A dose-dependent inhibition 
in the production of these cytokines was observed (Table 2), the four studied 
interleukins were the most significantly inhibited. To confirm the effects of LDD (5 
µg/ml - 25 µg/ml) on the production of proinflammatory cytokines by primary 
monocytes, either culture supernatant from A. actinomycetemcomitans or E. coli LPS 
(10 ng/ml) were concomitantly added to the cells, for 6 h. Both stimulants induced a 
marked increase in the production of IL-1α, IL-1β, IL-6 and IL-8 by the cells, whereas 
LDD caused a dose-dependent inhibition of this effect (Figures 1 A-D). Maximal 
inhibition was observed with 25 µg/ml doxycycline by 70%, 74%, 84% and 85%, 
respectively. To investigate the kinetics of cytokine inhibition by doxycycline, 
MonoMac-6 cells were challenged with A. actinomycetemcomitans supernatants for 
up-to 4 h in the presence of LDD (10 µg/ml). After this 4 h period, a cytokine array 
was used for the analyses (Figure 2). The levels of IL-2, IL-4, IL-7 and IFN-γ 
secretion were low or undetectable (< 5 pg/ml). A reduction in IL-1α, IL-1β, IL-6 and 
IL-8 levels was demonstrated already by 2 h, whereas a change in TNF-α levels was 
not detected until 4 h. TNF-α, IL-1α, IL-1β, IL-6 and IL-8 production was inhibited 
by 27%, 67%, 43%, 97%, and 98%, respectively (Figure 2). In contrast, the 
production of IL-10 was increased by 0.5-fold whereas that of IL-12 by 8-fold, in the 
presence of LDD, over 4 h (Figures 2F and 2G). 1 h following challenge with A. 
actinomycetemcomitans, the GM-CSF levels were increased by 2-fold and maintained 
unchanged over 4 h (Figure 2H). Interestingly, the presence of LDD further enhanced 
by 1.7-fold the A. actinomycetemcomitans-induced GM-CSF levels observed after 1 
h, but this difference was ablated after a further 4 h (Figure 2H). 
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4. Discussion 
The present study demonstrates that LDD doxycycline inhibits the production of 
several pro-inflammatory cytokines in human monocytic cells stimulated with A. 
actinomycetemcomitans culture supernatants. The importance of these findings is that, 
apart from its inhibitory effect on MMP activity, LDD also appears to exert more 
general anti-inflammatory effects, manifested as reduction of pro-inflammatory 
cytokine production by monocytes in the presence of A. actinomycetemcomitans. 
Thus LDD may have marked modulatory effects on the inflammatory response 
through a wide range of actions. For example, inhibition of IL-1β, TNF-α and IL-6 
may result in decreased bone resorptive activity , whereas inhibition of IL-8 may 
attenuate the influx of inflammatory cells into the affected area (41). These findings 
are in agreement with previous reports showing that LDD inhibits the release of TNF-
α, IL-1β, IL-6 and IL-8 by human macrophages induced by isolated A. 
actinomycetemcomitans LPS (42). In other experimental systems involving 
Chlamydia trachomatis infection of monocytic THP-1 cells, it has been shown that 
the production of these four pro-inflammatory cytokines is reduced in response to 
LDD (43).Taken together, it can be deduced that LDD has general anti-inflammatory 
properties. Inhibition of bacteria-induced cytokine secretion by doxycycline occurred 
in a dose-dependent manner, within a concentration range between 5-25 µg/ml, which 
did not show any evidence of cytotoxicity. LDD concentrations of 2 -10 µg/ml have 
been reported in GCF, gingival tissue or plasma after oral administration of this drug 
(44). Thus, the concentration of doxycycline used in this study is approximately 
within the concentration range of the drug found in tissues and biological fluids of 
patients after oral administration. Hence the present results are potentially of direct 
biological significance in vivo. The exact mechanism of LDD-induced inhibition of 
cytokines by monocytes is not clear, although related studies have indicated that its 
effects occur via a post-transcriptional or translational mechanisms (45, 46). The 
kinetics experiments showed that LDD displayed an early inhibitory action on IL-1α, 
IL-1β, IL-6 and IL-8 production within 2 hours, whereas a change in TNF-α level was 
only observed at 4 h. These early responses are likely to indicate a direct effect of the 
drug on pro-inflammatory cytokine production, rather than mediation by other 
secreted factors. However, IL-12 production displayed a different response profile, as 
this was rapidly up-regulated in the presence of LDD. It has been proposed that an 
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increase in IL-12 production could be an event associated with the inhibition of pro 
inflammatory cytokines, such as TNF-α (47). IL-12 is considered a link between 
innate and adaptive immunity (48, 49), and may be related to the pathogenesis of 
periodontal disease (50-52). Another interesting observation in the present study is 
that the production of the anti-inflammatory cytokine IL-10 was increased in response 
to LDD, possibly potentiating its beneficial effects to the host (53). This is an 
important finding as the relative IL-1beta/IL-10 ratio has been shown to be higher in 
aggressive periodontitis patients than periodontally healthy subjects (54). 
Modification of this ratio by LDD may help to improve the imbalance between pro- 
and anti-inflammatory cytokines in periodontitis. The levels of IL-2, IL-4, IL-7 and 
IFN-γ secretion were low or undetectable (<5 pg/ml). This is perhaps not surprising 
since earlier studies have shown that monocytes isolated from periodontitis patients 
do not produce IL-2 and IL-4 (55). Early induction of GM-CSF was observed in 
response to A. actinomycetemcomitans and further enhanced transiently by LDD. In 
support of these findings, A. actinomycetemcomitans cytolethal distending toxin was 
not able to induce production of GM-CSF by human PBMCs (56). Increased serum 
levels of IFN-γ have been associated with A. actinomycetemcomitans infection but 
natural killer cells of the innate immune system are thought to be their primary source 
(57). In conclusion, the present results indicate that LDD attenuates the production of 
a wide range of pro-inflammatory cytokines by human monocytes, induced by the 
major periodontal pathogen A. actinomycetemcomitans. Hence, within the limitation 
of this in vitro work, the present findings may lend support that the clinically proven 
benefits of this drug may be related to its ability to regulate inflammatory mediator 
release by monocytic cells, and not only due to the attenuation of MMP activity. This 
may well be in line with recent findings demonstrating that administration of LDD as 
an adjunct to non-surgical periodontal treatment stabilizes the inflammatory response 
by suppressing the levels of pro-inflammatory cytokines and enhancing anti 
inflammatory cytokines in GCF (36). 
 
References 
1. Haffajee A.D., Socransky S.S., Microbial etiological agents of destructive 
periodontal diseases. Periodontol 2000 1994, 5, 78-111. 
 10 
2. Marsh P.D., Dental plaque: biological significance of a biofilm and community 
life-style. J Clin Periodontol 2005, 32 Suppl 6, 7-15. 
3. Slots J., Listgarten M.A., Bacteroides gingivalis, Bacteroides intermedius and 
Actinobacillus actinomycetemcomitans in human periodontal diseases. J Clin 
Periodontol 1988, 15, 85-93. 
4. Haubek D., The highly leukotoxic JP2 clone of Aggregatibacter 
actinomycetemcomitans: evolutionary aspects, epidemiology and etiological role in 
aggressive periodontitis. APMIS Suppl 1-53. 
5. Haffajee A.D., Torresyap G., Socransky S.S., Clinical changes following four 
different periodontal therapies for the treatment of chronic periodontitis: 1-year 
results. J Clin Periodontol 2007, 34, 243-253. 
6. van Winkelhoff A.J., Rams T.E., Slots J., Systemic antibiotic therapy in 
periodontics. Periodontol 2000 1996, 10, 45-78. 
7. Walker C., Preshaw P.M., Novak J., Hefti A.F., Bradshaw M., Powala C., 
Longterm treatment with sub-antimicrobial dose doxycycline has no antibacterial 
effect on intestinal flora. J Clin Periodontol 2005, 32, 1163-1169. 
8. Fine D.H., Kaplan J.B., Kachlany S.C., Schreiner H.C., How we got attached to 
Actinobacillus actinomycetemcomitans: A model for infectious diseases. Periodontol 
2000 2006, 42, 114-157. 
9. Belibasakis G.N., Johansson A., Wang Y., Chen C., Kalfas S., Lerner U.H., The 
cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression 
in human gingival fibroblasts and periodontal ligament cells. Infect Immun 2005, 73, 
342-351. 
10. Belibasakis G.N., Johansson A., Wang Y. et al., Cytokine responses of human 
gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending 
toxin. Cytokine 2005, 30, 56-63. 
11. Fletcher J.M., Nair S.P., Ward J.M., Henderson B., Wilson M., Analysis of the 
effect of changing environmental conditions on the expression patterns of exported 
surface-associated proteins of the oral pathogen Actinobacillus 
actinomycetemcomitans. Microb Pathog 2001, 30, 359-368. 
12. van Winkelhoff A.J., Slots J., Actinobacillus actinomycetemcomitans and 
Porphyromonas gingivalis in nonoral infections. Periodontol 2000 1999, 20, 122-135. 
 11 
13. Oscarsson J., Karched M., Thay B., Chen C., Asikainen S., Proinflammatory 
effect in whole blood by free soluble bacterial components released from planktonic 
and biofilm cells. BMC Microbiol 2008, 8, 206. 
14. Kelk P., Claesson R., Chen C., Sjostedt A., Johansson A., IL-1beta secretion 
induced by Aggregatibacter (Actinobacillus) actinomycetemcomitans is mainly 
caused by the leukotoxin. Int J Med Microbiol 2008, 298, 529-541. 
15. Bartova J., Krejsa O., Sirova M., Tlaskalova H., Prochazkova J., Duskova J., 
Local antibodies and cytokine responses in crevicular fluid of patients with juvenile 
periodontitis. Adv Exp Med Biol 1995, 371B, 1109-1112. 
16. Casarin R.C., Ribeiro Edel P., Mariano F.S., Nociti F.H., Jr., Casati M.Z., 
Goncalves R.B., Levels of Aggregatibacter actinomycetemcomitans, Porphyromonas 
gingivalis, inflammatory cytokines and species-specific immunoglobulin G in 
generalized aggressive and chronic periodontitis. J Periodontal Res 45, 635-642. 
17. Silva N., Dutzan N., Hernandez M. et al., Characterization of progressive 
periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, 
matrix metalloproteinase-13, periodontal pathogens and inflammatory cells. J Clin 
Periodontol 2008, 35, 206-214. 
18. Nakamura T., Nitta H., Ishikawa I., Effect of low dose Actinobacillus 
actinomycetemcomitans lipopolysaccharide pretreatment on cytokine production by 
human whole blood. J Periodontal Res 2004, 39, 129-135. 
19. Fives-Taylor P.M., Meyer D.H., Mintz K.P., Brissette C., Virulence factors of 
Actinobacillus actinomycetemcomitans. Periodontol 2000 1999, 20, 136-167. 
20. Henderson B., Wilson M., Sharp L., Ward J.M., Actinobacillus 
actinomycetemcomitans. J Med Microbiol 2002, 51, 1013-1020. 
21. Barksby H.E., Nile C.J., Jaedicke K.M., Taylor J.J., Preshaw P.M., Differential 
expression of immunoregulatory genes in monocytes in response to Porphyromonas 
gingivalis and Escherichia coli lipopolysaccharide. Clin Exp Immunol 2009, 156, 
479-487. 
22. Bostanci N., Allaker R., Johansson U. et al., Interleukin-1alpha stimulation in 
monocytes by periodontal bacteria: antagonistic effects of Porphyromonas gingivalis. 
Oral Microbiol Immunol 2007, 22, 52-60. 
23. Bostanci N., Allaker R.P., Belibasakis G.N. et al., Porphyromonas gingivalis 
antagonises Campylobacter rectus induced cytokine production by human monocytes. 
Cytokine 2007, 39, 147-156. 
 12 
24. Hamedi M., Belibasakis G.N., Cruchley A.T., Rangarajan M., Curtis M.A., 
Bostanci N., Porphyromonas gingivalis culture supernatants differentially regulate 
interleukin-1beta and interleukin-18 in human monocytic cells. Cytokine 2009, 45, 
99-104. 
25. Graves D.T., Cochran D., The contribution of interleukin-1 and tumor necrosis 
factor to periodontal tissue destruction. J Periodontol 2003, 74, 391-401. 
26. Graves D.T., Delima A.J., Assuma R., Amar S., Oates T., Cochran D. Interleukin-
1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell 
infiltration toward alveolar bone in experimental periodontitis. J Periodontol 1998, 69, 
1419-1425. 
27. McInnes I.B., Schett G., Cytokines in the pathogenesis of rheumatoid arthritis. 
Nat Rev Immunol 2007, 7, 429-442. 
28. Salvi G.E., Collins J.G., Yalda B., Arnold R.R., Lang N.P., Offenbacher S. 
Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. 
J Clin Periodontol 1997, 24, 8-16. 
29. Preshaw P.M., Hefti A.F., Bradshaw M.H., Adjunctive subantimicrobial dose 
doxycycline in smokers and non-smokers with chronic periodontitis. J Clin 
Periodontol 2005, 32, 610-616. 
30. Golub L.M., McNamara T.F., Ryan M.E. et al., Adjunctive treatment with 
subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity 
and attachment loss in adult periodontitis. J Clin Periodontol 2001, 28, 146-156. 
31. Gurkan A., Emingil G., Cinarcik S., Berdeli A., Post-treatment effects of 
subantimicrobial dose doxycycline on clinical parameters and gingival crevicular 
fluid transforming growth factor-beta1 in severe, generalized chronic periodontitis. Int 
J Dent Hyg 2008, 6, 84-92. 32. Hanemaaijer R., Sorsa T., Konttinen Y.T. et al., 
Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and 
endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol 
Chem 1997, 272, 31504-31509. 
33. Hyc A., Osiecka-Iwan A., Niderla-Bielinska J., Moskalewski S., Influence of 
LPS, TNF, TGF-ss1 and IL-4 on the expression of MMPs, TIMPs and selected 
cytokines in rat synovial membranes incubated in vitro. Int J Mol Med 27, 127-137. 
34. Krakauer T., Buckley M., Doxycycline is anti-inflammatory and inhibits 
staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents 
Chemother 2003, 47, 3630-3633. 
 13 
35. Shapira L., Barak V., Soskolne W.A., Halabi A., Stabholz A., Effects of 
tetracyclines on the pathologic activity of endotoxin: in vitro and in vivo studies. Adv 
Dent Res 1998, 12, 119-122. 
36. Emingil G., Gurkan A., Atilla G., Kantarci A., Subantimicrobial-dose doxycycline 
and cytokine-chemokine levels in gingival crevicular fluid. J Periodontol 2011, 82, 
452-461. 
37. Gilbertson-Beadling S., Powers E.A., Stamp-Cole M. et al., The tetracycline 
analogs minocycline and doxycycline inhibit angiogenesis in vitro by a 
nonmetalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995, 36, 
418-424. 
38. Mandell R.L., Tripodi L.S., Savitt E., Goodson J.M., Socransky S.S., The effect of 
treatment on Actinobacillus actinomycetemcomitans in localized juvenile 
periodontitis. J Periodontol 1986, 57, 94-99. 
39. Cortelli S.C., Costa F.O., Kawai T. et al., Diminished treatment response of 
periodontally diseased patients infected with the JP2 clone of Aggregatibacter 
(Actinobacillus) actinomycetemcomitans. J Clin Microbiol 2009, 47, 2018-2025. 
40. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmuller 
G., Establishment of a human cell line (Mono Mac 6) with characteristics of mature 
monocytes. Int J Cancer 1988, 41, 456-461. 
41. Kornman K.S., Page R.C., Tonetti M.S., The host response to the microbial 
challenge in periodontitis: assembling the players. Periodontol 2000 1997, 14, 33-53. 
42. Cazalis J., Bodet C., Gagnon G., Grenier D., Doxycycline reduces 
lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex 
vivo human whole blood models. J Periodontol 2008, 79, 1762-1768. 
43. Mpiga P., Mansour S., Morisset R., Beaulieu R., Ravaoarinoro M., Sustained 
interleukin-6 and interleukin-8 expression following infection with Chlamydia 
trachomatis serovar L2 in a HeLa/THP-1 cell co-culture model. Scand J Immunol 
2006, 63, 199-207. 
44. Lavda M., Clausnitzer C.E., Walters J.D., Distribution of systemic ciprofloxacin 
and doxycycline to gingiva and gingival crevicular fluid. J Periodontol 2004, 75, 
1663-1667. 
45. Shapira L., Soskolne W.A., Houri Y., Barak V., Halabi A., Stabholz A., 
Protection against endotoxic shock and lipopolysaccharide-induced local 
 14 
inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect 
Immun 1996, 64, 825-828. 
46. Uitto V.J., Firth J.D., Nip L., Golub L.M., Doxycycline and chemically modified 
tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin 
keratinocytes. Ann N Y Acad Sci 1994, 732, 140-151. 
47. Ma X., Sun J., Papasavvas E. et al., Inhibition of IL-12 production in human 
monocyte-derived macrophages by TNF. J Immunol 2000, 164, 1722-1729. 
48. Ma X., Riemann H., Gri G., Trinchieri G., Positive and negative regulation of 
interleukin-12 gene expression. Eur Cytokine Netw 1998, 9, 54-64. 
49. Trinchieri G., Interleukin-12 and the regulation of innate resistance and adaptive 
immunity. Nat Rev Immunol 2003, 3, 133-146. 
50. Yucel O.O., Berker E., Gariboglu S., Otlu H., Interleukin-11, interleukin-1beta, 
interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J Clin 
Periodontol 2008, 35, 365-370. 
51. Tsai I.S., Tsai C.C., Ho Y.P., Ho K.Y., Wu Y.M., Hung C.C., Interleukin-12 and 
interleukin-16 in periodontal disease. Cytokine 2005, 31, 34-40. 
52. Fokkema S.J., Loos B.G., de Slegte C. et al., Increased release of IL-12p70 by 
monocytes after periodontal therapy. J Clin Periodontol 2003, 30, 1091-1096. 
53. Couper K.N., Blount D.G., Riley E.M., IL-10: the master regulator of immunity to 
infection. J Immunol 2008, 180, 5771-5777. 
54. Teles R., Sakellari D., Teles F. et al., Relationships among gingival crevicular 
fluid biomarkers, clinical parameters of periodontal disease, and the subgingival 
microbiota. J Periodontol 81, 89-98. 
55. Fujihashi K., Beagley K.W., Kono Y. et al., Gingival mononuclear cells from 
chronic inflammatory periodontal tissues produce interleukin (IL)-5 and IL-6 but not 
IL-2 and IL-4. Am J Pathol 1993, 142, 1239-1250. 
56. Akifusa S., Poole S., Lewthwaite J., Henderson B., Nair S.P., Recombinant 
Actinobacillus actinomycetemcomitans cytolethal distending toxin proteins are 
required to interact to inhibit human cell cycle progression and to stimulate human 
leukocyte cytokine synthesis. Infect Immun 2001, 69, 5925-5930. 
57. Andrukhov O., Ulm C., Reischl H., Nguyen P.Q., Matejka M., Rausch-Fan X., 
Serum cytokine levels in periodontitis patients in relation to the bacterial load. J 
Periodontol 82, 885-892.  
 15 
Tables 
Table 1 
LDH release 
% of total LDH 
Control  +Dox 10 µg/ml   +Dox 25 µg/ml 
Monomac-6   14.7 ± 2.3  10.3 ± 3.9    12.7 ± 0.9 
Primary monocytes  13.6±1.2  13.4 ±0.7    14.6±1.6 
Effects of doxycycline on cell viability. MonoMac-6 cells or primary human 
monocytes were incubated with the indicated two doses of doxycycline for 6 hours. 
Cytotoxicity was determined by the release of the cytosol enzyme lactate 
dehydrogenase (LDH), expressed as a percentage of the total (intracellular + 
extracellular) LDH activity. The data is expressed as mean ± standard deviation (n = 
3). 
 
Table 2 
Cytokine 
Control  A.a   A.a+Dox 10µg/ml A.a+Dox 25µg/ml 
IL-1α  8.7 ± 0.7 *  496.6 ± 24.1   21.4 ± 6.0 *   10.2 ± 2.3 * 
IL-1β 17.5 ± 1.1 *  1120.3 ±129.7  228.0 ± 20.3*   149.8 ± 13.3 * 
IL-6  11.2 ± 4.5 *  271.1 ± 6.4   6.4 ± 3.9 *   6.1 ± 2.5 * 
IL-8  554.3± 99.7 * 3110.8 ± 153.1 37.6 ± 17.6 *   27.6 ± 23.0 * 
TNF-α 78.24 ± 3.5* 3142.0 ± 51.6  1395.1 ± 47.9 *  837.3 ± 19.8 * 
MonoMac-6 cells were exposed to culture supernatants from 
A.actinomycetemcomitans in the presence or absence of doxycycline (10 or 25 µg/ml). 
After 6 hours of challenge, cell-free culture supernatants were collected to assess 
cytokine release by ELISA. The data is expressed in pg/ml represent the means ± 
standard deviation (n=3) Asterisk (*) represents statistically significant differences as 
compared to the A. actinomycetemcomitants-challenged group (P < 0.05). 
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Figure Legend 
Figure 1 
 
 
 
The levels of IL-1α, IL-1β, IL-6 and IL-8 in human monocytes regulated on activation 
by A. actinomycetemcomitans or E.coli LPS in the presence or absence of doxycycline 
(Figures A-D). Freshly isolated CD14+ monocytes were plated at a density of 1 x 106 
cells/ml in 96-well dishes. Cells were exposed to culture supernatants from A.a or E.c 
LPS (10 ng/ml) in the presence or absence of doxycycline (5 to 25 µg/ml). After 6 h 
incubation, cell-free supernatants were collected to assess cytokine release by ELISA. 
The data are means ± SD (n=3) representative of one of three separate experiments. 
Asterisk (*) represents statistically significant differences as compared to the A. 
actinomycetemcomitants or E.coli LPS challenged group (P < 0.05). 
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Figure 2 
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Kinetics of cytokine release in the presence of doxycycline. MonoMac-6 cells were 
exposed to culture supernatants of A. actinomycetemcomitans (A.a) in the presence or 
absence of doxycycline (10 µg/ml). Cell-free supernatants were collected at indicated 
time points (0.5 h, 1 h, 2 h, 4 h) to assess cytokine release by a cytokine array. Levels 
of detectable cytokines are shown for IL-1α (A), IL-1β (B), IL-6 (C), IL-8 (D), TNF-α 
(E), IL-10 (F), IL-12 (G), and GM-CSF (H). Asterisk (*) represents statistically 
significant differences of the two groups at any time-point (P < 0.05). 
